



FOR IMMEDIATE RELEASE

Oxford Finance Corporation Leads \$30 Million Secured Loan Facility for Cadence Pharmaceuticals

Alexandria, VA, July 28, 2010 –Oxford Finance Corporation, a subsidiary of Sumitomo Corporation, today announced that it was the lead lender for a \$30 million credit facility provided to Cadence Pharmaceuticals. Silicon Valley Bank and GE Financial Services, Inc. also participated in the loan agreement. This infusion of capital will support the company’s potential launch of their investigational product candidate, OFIRMEV™, an intravenous formulation of acetaminophen that is currently marketed in Europe for the treatment of acute pain and fever.

“Oxford was pleased to deliver a financing package to help Cadence introduce OFIRMEV™ to the U.S. market,” said Christopher Herr, Managing Director of Oxford Finance Corporation. “The proven track record of this product in Europe, combined with the experienced management team, presented an excellent lending opportunity for us.”

About Oxford Finance Corporation

A subsidiary of Sumitomo Corporation, Oxford is a specialty finance firm providing senior secured loans to public and private life science and healthcare services companies worldwide. For over 20 years, Oxford has delivered flexible financing solutions to its clients, enabling these companies to maximize their equity by leveraging their assets. In recent years, Oxford has originated over \$1.5 billion in loans, with lines of credit ranging from \$500 thousand to \$40 million. Oxford is headquartered in Alexandria, Virginia, with additional offices in California and Massachusetts. For more information visit www.oxfordfinance.com.

Media Contact:

Shelly Davis
Director, Marketing
Oxford Finance Corporation
888-471-0174
sdavis@oxfordfinance.com